First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory (R/R) CLL and other hematologic malignancies (HMs).Sikander Ailawadhi, Yifan Zhai, Marina Konopleva et al.|Journal of Clinical Oncology|2021Cited by 25
Lisaftoclax (APG-2575) Safety and Activity As Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (pts) with Treatment-Naïve, Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL): Initial Data from a Phase 2 Global StudyMatthew S. Davids, Yifan Zhai, Asher Chanan‐Khan et al.|Blood|2022Cited by 16